Lamifen Tablets: Your Complete Guide to Dosage and Side Effects

Welcome to our comprehensive guide on Lamifen Tablets, an essential medication in the treatment of fungal infections. Lamifen Tablets contain the active ingredient terbinafine, which is known for its broad spectrum antifungal properties. In this article, we will delve into the composition, indications, dosage, special considerations, pharmacodynamics, pharmacokinetics, safety data, packaging information, and more regarding Lamifen Tablets. Whether you’re a healthcare professional or a patient seeking information, this guide aims to provide you with in-depth knowledge about Lamifen Tablets and their role in antifungal therapy.

---

Composition of Lamifen Tablets

Lamifen Tablets are available in two variants: 125mg and 250mg. The active ingredient in Lamifen Tablets is terbinafine, which exerts its antifungal effects by interfering with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol, an essential component of fungal cell membranes, ultimately resulting in fungal cell death.

Apart from terbinafine, Lamifen Tablets contain several inactive ingredients, including:

• Microcrystalline Cellulose (Avicel PH 102)
• Colloidal Silicon Dioxide (Aerosil 200)
• Hydroxypropyl Methyl Cellulose (Methocel E 15)
• Magnesium Stearate
• Croscarmellose Sodium
• Tween 80 (Emaral 80)

These inactive ingredients serve various functions such as binding the tablet components together, aiding in disintegration, and enhancing stability.

---

Indications for Lamifen Tablets

Lamifen Tablets are indicated for the treatment of several fungal infections, including:

1. Onychomycosis: Fungal infection of the nails caused by dermatophyte fungi.
2. Tinea Capitis: Fungal infections of the scalp.
3. Skin Fungal Infections: Including tinea corporis, tinea cruris, tinea pedis, and yeast infections of the skin caused by Candida species.

It’s important to note that Lamifen Tablets are generally considered appropriate for oral therapy in cases where topical treatment may not be effective due to the site, severity, or extent of the infection. However, Lamifen Tablets are not effective in treating pityriasis versicolor, a fungal skin infection caused by Malassezia species.

---

Dosage and Administration

The dosage and duration of treatment with Lamifen Tablets vary according to the indication and severity of the fungal infection. For adults, the recommended dosage is typically 250mg once daily. The duration of treatment for specific infections is as follows:

• Tinea Pedis (Athlete’s Foot): 2 to 6 weeks
• Tinea Corporis (Ringworm of the Body) and Tinea Cruris (Jock Itch): 2 to 4 weeks
• Cutaneous Candidiasis: 2 to 4 weeks
• Tinea Capitis (Scalp Ringworm): 4 weeks
• Onychomycosis (Fungal Nail Infections):
  • Fingernail Onychomycosis: 6 weeks
  • Toenail Onychomycosis: 12 weeks

Complete resolution of symptoms may not occur until several weeks after mycological cure, and optimal clinical effect is typically observed months after treatment cessation.

---

Special Considerations with Lamifen Tablets

Liver Impairment:

Patients with chronic or active liver disease are not recommended to take Lamifen Tablets due to the risk of hepatotoxicity. Before prescribing Lamifen Tablets, healthcare professionals should assess the patient’s liver function, and patients should be monitored for signs of liver dysfunction during treatment.

Renal Impairment:

The use of Lamifen Tablets has not been adequately studied in patients with renal impairment, and therefore, it is not recommended in this population. Healthcare professionals should exercise caution when prescribing Lamifen Tablets to patients with impaired renal function.

Geriatric Patients:

There is no evidence to suggest that elderly patients require different dosages or experience different side effects than younger patients when taking Lamifen Tablets. However, healthcare professionals should consider the possibility of pre-existing impairment of liver or kidney function in elderly patients and adjust treatment accordingly.

Contraindications

Lamifen Tablets are contraindicated in individuals with a known hypersensitivity to terbinafine or any of the excipients present in the formulation. Patients who have experienced allergic reactions or intolerance to terbinafine or similar antifungal medications should avoid using Lamifen Tablets. It’s essential for healthcare providers to assess patients for any history of hypersensitivity reactions before prescribing Lamifen Tablets to ensure their safety and efficacy.

---

Special Warnings & Precautions For Use

Liver Function:

One of the critical considerations when prescribing Lamifen Tablets is the patient’s liver function. Lamifen Tablets are not recommended for patients with chronic or active liver diseases due to the risk of hepatotoxicity. Patients should be closely monitored for signs and symptoms of liver dysfunction, such as persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. If any of these symptoms occur, patients should discontinue Lamifen Tablets immediately, and liver function should be evaluated promptly.

Dermatological Effects:

Serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in patients taking terbinafine tablets. Healthcare providers should educate patients about the signs and symptoms of these serious skin reactions, including progressive skin rash, blistering, and mucosal involvement. If such reactions occur, Lamifen Tablets treatment should be discontinued, and patients should seek medical attention promptly.

Haematological Effects:

Although rare, cases of blood dyscrasias, including neutropenia, agranulocytosis, thrombocytopenia, and pancytopenia, have been reported in patients treated with terbinafine tablets. Healthcare providers should monitor patients for any signs of blood disorders, such as unexplained bruising, bleeding, or infections. If blood dyscrasias occur, consideration should be given to discontinuing treatment with Lamifen Tablets and initiating appropriate management.

Renal Function:

Patients with renal impairment, characterized by a creatinine clearance less than 50 ml/min or serum creatinine levels exceeding 300 micro mol/l, should avoid using Lamifen Tablets. The safety and efficacy of Lamifen Tablets have not been adequately studied in this patient population. Healthcare providers should exercise caution when prescribing Lamifen Tablets to patients with renal impairment and consider alternative treatment options.

Drug Interactions:

Terbinafine inhibits the CYP2D6 metabolism, which can lead to potential drug interactions with medications metabolized by this enzyme. Healthcare providers should be cautious when co-administering Lamifen Tablets with drugs predominantly metabolized by CYP2D6, such as tricyclic antidepressants, beta-blockers, selective serotonin reuptake inhibitors, antiarrhythmics, and monoamine oxidase inhibitors. Close monitoring of patients for adverse effects and therapeutic drug monitoring may be necessary in such cases.

Pharmacodynamics of Lamifen Tablets

Terbinafine, the active ingredient in Lamifen Tablets, exhibits broad-spectrum antifungal activity against various fungal pathogens, including dermatophytes and yeasts. It interferes with fungal sterol biosynthesis by inhibiting squalene epoxidase, an enzyme crucial for the synthesis of ergosterol, a vital component of fungal cell membranes. This disruption in membrane integrity ultimately leads to fungal cell death.

At low concentrations, terbinafine demonstrates fungicidal activity against dermatophytes, molds, and certain dimorphic fungi. Its activity against yeasts, however, can be fungicidal or fungistatic, depending on the species. Terbinafine’s mechanism of action, which specifically targets fungal cell membranes, makes it an effective treatment option for various fungal infections affecting the skin, hair, and nails.

---

Pharmacokinetics of Lamifen Tablets

Following oral administration, terbinafine is well absorbed, with an absolute bioavailability of approximately 50% due to first-pass metabolism. Peak plasma concentrations are achieved within 1.5 hours of ingestion, with steady-state concentrations typically reached after multiple doses. The effective half-life of terbinafine is approximately 30 hours, allowing for once-daily dosing.

Terbinafine is extensively metabolized by several cytochrome P450 (CYP) isoenzymes, including CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19. The metabolites produced are devoid of antifungal activity and are primarily eliminated via the urine. Patients with renal impairment or pre-existing liver disease may exhibit altered clearance rates of terbinafine, necessitating dosage adjustments and close monitoring.

The drug’s distribution into skin, hair, and nails, as well as its secretion in sebum, contributes to its efficacy in treating fungal infections at these sites. Terbinafine’s ability to penetrate the nail plate early in treatment allows for targeted action against onychomycosis, a common fungal nail infection.

---

Preclinical Safety Data

Long-term studies in animals have demonstrated the safety profile of terbinafine at therapeutic doses. In rats and dogs, no marked toxic effects were observed at oral doses of up to 100 mg/kg/day for up to one year. Carcinogenicity studies in mice and rats did not show any neoplastic findings attributable to terbinafine treatment.

However, an increased incidence of liver tumors was observed in male rats at the highest dose level of 69 mg/kg/day in a two-year oral carcinogenicity study. This finding was not replicated in other species or in other studies, suggesting species-specific effects. Additionally, reversible refractile irregularities were observed in the retina of monkeys at high doses, indicating ocular effects that were not associated with functional changes.

Packaging Information and Manufacturer Details

Lamifen Tablets are meticulously packaged to ensure their integrity and stability. Each carton box contains either 14 tablets of Lamifen 125mg or Lamifen 250mg, organized in two aluminum/PVC strips, with each strip containing 7 tablets. Additionally, an inner leaflet is included in the packaging, providing essential information about the medication, including dosage instructions, precautions, and possible side effects.

These tablets are manufactured by the Egyptian Group for Pharmaceutical Industries, a renowned pharmaceutical company known for its commitment to quality and efficacy. The company adheres to stringent manufacturing standards and quality control measures to produce pharmaceutical products that meet global regulatory requirements and safety standards.

---

Conclusion

In conclusion, Lamifen Tablets containing terbinafine are invaluable in the treatment of various fungal infections affecting the skin, hair, and nails. With their broad-spectrum antifungal activity, convenient once-daily dosing, and well-established safety profile, Lamifen Tablets offer an effective therapeutic option for patients suffering from fungal infections.

Healthcare professionals prescribing Lamifen Tablets should carefully assess patient suitability, considering factors such as liver and renal function, concomitant medications, and potential drug interactions. Close monitoring for adverse effects, particularly hepatotoxicity and dermatological reactions, is essential throughout the treatment course.

By understanding the composition, indications, dosage, pharmacodynamics, pharmacokinetics, safety data, and packaging information of Lamifen Tablets, healthcare providers can optimize treatment outcomes and ensure patient safety and satisfaction.

If you have any further questions or concerns about Lamifen Tablets or antifungal therapy in general, don’t hesitate to consult with your healthcare provider. Stay informed, stay healthy!